Cees de Jong

Cees de Jong currently works at Novonesis (Novozymes A, as Chairman from 2024, Spring MidCo DK ApS, as Chairman, OTTera, Inc., as Chairman, Oterra Holding ApS, as Chairman, Oterra Operations ApS, as Chairman, Novo Nordisk A, as Vice Chairman from 2025, Meatable BV, as Chairman from 2021, and Protein Sciences Corp., as Director.
Dr. de Jong also formerly worked at Chr.
Hansen A, as President & Chief Executive Officer, Chr.
Hansen Holding A, as President & Chief Executive Officer from 2013 to 2018, Mediq BV (OLD), as Chairman-Supervisory Board, ForFarmers NV, as Chairman-Supervisory Board from 2018 to 2021, Polyganics BV, as Chairman, Crelan Finance (NL) BV, as Chairman & Co-Managing Director, The Akkermansia Co., as Chairman-Supervisory Board, Novozymes A, as Independent Vice Chairman from 2020 to 2023, Spring TopCo DK ApS, as Chairman, Quest International BV, as Director, DSM Anti Infectives BV, as Managing Director, Crucell NV, as Chief Operating Officer from 2007 to 2010, Janssen Vaccines & Prevention BV, as Chief Operating Officer, and Gist-Brocades NV, as MD-Industrial Pharmaceutical Division.
Dr. de Jong received his doctorate degree from Erasmus University Rotterdam and Masters Business Admin degree from Rotterdam School of Management.